CoChat

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Open access

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Abstract

Background Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg.Methods In this 52-week, multicentre, randomised, open-label, phase 3a trial, we recruited patients with type 2 diabetes from 81 sites in ten countries. Patients were eligible if they were aged 18 years or older (19 years or older in South Korea), had type 2 diabetes (diagnosed ≥90 days before screening), HbA 1c of 7·5-9·5% (58-80 mmol/mol), and were inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (for 90 days or more before screening). Participants were randomly assigned (1:1) by use of an interactive web-response system, stratified by background glucose-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 14 mg once daily or sitagliptin 100 mg once daily. To approximate treatment individualisation in clinical practice, oral semaglutide dose could be adjusted on the basis of prespecified HbA 1c and tolerability criteria. Two efficacy-related estimands were prespecified: treatment policy (regardless of treatment discontinuation or use of rescue medication) and trial product (on treatment and without use of rescue medication) for participants randomly assigned to treatment. The primary endpoint was achievement of HbA 1c of less than 7% (53 mmol/mol) at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02849080, and European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing.Findings Between Sept 20, 2016, and Feb 7, 2017, of 804 patients assessed for eligibility, 504 were eligible and randomly assigned to oral semaglutide (n=253) or sitagliptin (n=251). Most participants were male (285 [57%] of 504) with a mean age of 57·4 years (SD 9·9). All participants were given at least one dose of their allocated study drug except for one participant in the sitagliptin group. From a mean baseline HbA 1c of 8·3% (SD 0·6%; 67 mmol/mol [SD 6·4]), a greater proportion of participants achieved an HbA 1c of less than 7% with oral semaglutide than did with sitagliptin (treatment policy estimand: 58% [134 of 230] vs 25% [60 of 238]; and trial product estimand: 63% [123 of 196] vs 28% [52 of 184]). The odds of achieving an HbA 1c of less than 7% was significantly better with oral semaglutide than sitagliptin (treatment policy estimand: odds ratio [OR] 4·40, 95% CI 2·89-6·70, p<0·0001; and trial product estimand: 5·54, 3·54-8·68, p<0·0001). The odds of decreasing mean bodyweight from baseline to week 52 were higher with oral semaglutide than with sitagliptin (estimated mean change in bodyweight, treatment policy estimand: -2·6 kg [SE 0·3] vs -0·7 kg [SE 0·2], estimated treatment difference [ETD] -1·9 kg, 95% CI -2·6 to -1·2; p<0·0001; and trial product estimand: -2·9 kg [SE 0·3] vs -0·8 kg [SE 0·3], ETD -2·2 kg, -2·9 to -1·5; p<0·0001). Adverse events occurred in 197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagliptin group, and nausea was the most common adverse event with oral semaglutide (53 [21%]). Two deaths occurred in the sitagliptin group during the trial.Interpretation Oral semaglutide, with flexible dose adjustment, based on efficacy and tolerability, provided superior glycaemic control and weight loss compared with sitagliptin, and with a safety profile consistent with subcutaneous GLP-1 receptor agonists.Funding Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30194-9

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 287

Metadata

Authors
Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., Arif, A. A., Aronne, L. J., Aronoff, S., Ataoglu, E., Baik, S. H., Bays, H., Beckett, P. L., Berker, D., Bilz, S., Bode, B., Braun, E. W., Buse, J. B., Canani, L. H. S., Cho, Y. M., Chung, C. H., Colin, I., Condit, J., Cooper, J., Delgado, B., Eagerton, D. C., El Ebrashy, I. N., El Hefnawy, M. H. M. F., Eliaschewitz, F. G., Finneran, M. P., Fischli, S., Fließer-Görzer, E., Geohas, J., Godbole, N. A., Golay, A., Gorban de Lapertosa, S., Gross, J. L., Gulseth, H. L., Helland, F., Høivik, H. O., Issa, C., Kang, E. S., Keller, C., Khalil, S. H. A., Kim, N. H., Kim, I. J., Klaff, L. J., Laimer, M., LaRocque, J. C., Lederman, S. N., Lee, K.-W., Litchfield, W. R., Manning, M. B., Mertens, A., Morawski, E. J., Murray, A. V., Nicol, P. R., O'Connor, T. M., Oğuz, A., Ong, S., Özdemir, A., Palace, E. M., Palchick, B. A., Pereles-Ortiz, J., Pieber, T., Prager, R., Preumont, V, Riffer, E., Rista, L., Rudofsky, G., Sarı, R., Scheen, A., Schultes, B., Seo, J. A., Shelbaya, S. A., Sivalingam, K., Sorli, C. H., Stäuble, S., Streja, D. A., T'Sjoen, G., Tetiker, T., Van Gaal, L., Vercammen, C., Warren, M. L., Weinstein, D. L., Weiss, D., White, A., Winnie, M., Wium, C., & Yavuz, D.
Affiliations
  • Seoul National University (KR)
  • Novo Nordisk (Denmark) (DK)
  • University of North Carolina at Chapel Hill (US)
  • Atlanta Diabetes Associates (US)
  • Medical University of Graz (AT)
  • KU Leuven (BE)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-07
Volume
7
Issue
7
Pages
528-539
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2948380809
Cited by
287
References
25
Citations by year
2026: 26 · 2025: 49 · 2024: 41 · 2023: 30 · 2022: 29 · 2021: 46 · 2020: 50 · 2019: 16
FWCI
28.60
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, other-oa)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • GlaxoSmithKline
  • Novo Nordisk
  • Johnson and Johnson
  • Sanofi
  • University of North Carolina Wilmington
  • AstraZeneca
  • Zafgen
  • National Institutes of Health (UL1TR002489)
  • Eli Lilly and Company
  • Intarcia Therapeutics
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, sitagliptin, type 2 diabetes, GLP-1 receptor agonists, HbA1c, body weight, glycemic control, drug safety, adverse events, treatment discontinuation, rescue medication, personalized treatment, oral glucose-lowering agents, hypoglycemia
MeSH terms
Sitagliptin Phosphate, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30194-9
The paper
Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., Arif, A. A., Aronne, L. J., Aronoff, S., Ataoglu, E., Baik, S. H., Bays, H., Beckett, P. L., Berker, D., Bilz, S., . . . Yavuz, D. (2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30194-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.